Efficacy and Safety of Secukinumab for the Treatment of Moderate to Severe Psoriasis in Korea / 대한피부과학회지
Korean Journal of Dermatology
;
: 9-14, 2019.
Article
in Korean
| WPRIM
| ID: wpr-719530
ABSTRACT
BACKGROUND:
Secukinumab, a fully human monoclonal antibody that targets interleukin (IL)-17A, which is a central cytokine in the pathogenesis of psoriasis, has emerged as a promising treatment for moderate to severe psoriasis. However, to date, there are no real-world data for secukinumab in Korean patients with psoriasis.OBJECTIVE:
To assess the clinical efficacy and safety of secukinumab in Korean patients with psoriasis.METHODS:
Prospective data were gathered during follow-up from 28 consecutive patients with chronic plaque-type psoriasis treated with secukinumab for minimum of 12 weeks at a single referral center. Patient demographics, Psoriasis Area Severity Index (PASI) score, Physicians' Global Assessment (PGA), Dermatologic Life Quality Index (DLQI), and adverse events were investigated.RESULTS:
The mean PASI score was significantly decreased after the induction period of secukinumab treatment (paired t-test, p<0.05). Of the 28 patients, 17 (60.7%) had obtained near complete clearance (PASI 90) at the last follow-up visit. No unexpected adverse events, other than nasopharyngitis, were observed.CONCLUSION:
Secukinumab can be of benefit for the treatment of Korean patients with psoriasis, as the treatment was associated with a rapid and satisfactory response and safety profile.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Psoriasis
/
Quality of Life
/
Referral and Consultation
/
Demography
/
Nasopharyngitis
/
Prospective Studies
/
Follow-Up Studies
/
Interleukins
/
Treatment Outcome
/
Korea
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Korean Journal of Dermatology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS